Comparative Pharmacology
Head-to-head clinical analysis: RENOCAL 76 versus RENOGRAFIN 76.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RENOCAL 76 versus RENOGRAFIN 76.
RENOCAL-76 vs RENOGRAFIN-76
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Contains iothalamate meglumine, an ionic high-osmolar contrast medium that absorbs X-rays, thereby enhancing vascular and tissue contrast during radiographic procedures. It functions by increasing the attenuation of X-rays in blood and tissues where it distributes.
Radiopaque contrast agent that attenuates X-rays by absorbing them due to its high iodine content, allowing visualization of vascular structures and organs during radiographic procedures.
Intravenous: 50-100 mL of a 37% iodine-containing solution (approximately 14-28 g iodine) administered as a slow intravenous injection over 1-2 minutes, or as an intravenous infusion over 10-30 minutes, typically not exceeding 4.5 mL/kg body weight.
Intravenous administration of 50-100 mL (14.1-28.2 g iodine) as a single dose for angiography; dose varies by procedure and patient size.
None Documented
None Documented
Terminal elimination half-life ranges from 1.2 to 2.5 hours in patients with normal renal function. In patients with severe renal impairment, half-life may be prolonged up to 20 hours.
Terminal elimination half-life: 1–2 hours (normal renal function); prolonged to >20 hours in severe renal impairment (CrCl <10 mL/min)
Primarily renal excretion via glomerular filtration. Approximately 95% of administered dose is excreted unchanged in urine within 24 hours. Less than 5% undergoes biliary/fecal elimination.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: negligible (<5%)
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent